Cargando…
Acute respiratory distress syndrome in a patient with primary myelofibrosis after ruxolitinib treatment discontinuation
Ruxolitinib is a Janus kinase (JAK) inhibitor used for the treatment of myelofibrosis with demonstrated efficacy for the alleviation of disease-related symptoms and splenomegaly. Anemia and thrombocytopenia are the main secondary effects. However, there are case reports of rare but serious adverse e...
| Autores principales: | , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Springer Japan
2014
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7100122/ https://www.ncbi.nlm.nih.gov/pubmed/25034748 http://dx.doi.org/10.1007/s12185-014-1628-5 |